LianBio Reports Third Quarter 2023 Financial Results and Pro

Entered into agreement with Bristol Myers Squibb for mavacamten in China and other Asian marketsPhase 3 data from EXPLORER-CN trial of mavacamten presented in an oral late-breaking science session at the European Society of Cardiology Congress 2023 with simultaneous publication in JAMA Cardiology Topline data announced from Phase 3 trial of TP-03 in Chinese Demodex blepharitis patientsCash, cash equivalents and marketable securities of $252.2 million as of September 30, 2023Strategic review ongo

Related Keywords

United States , Thailand , Shanghai , China , Hong Kong , Taiwan , Singapore , Macau , Chinese , Katherine Smith , Bristol Myers Squibb , Yizhe Wang , European Society Of Cardiology Congress , European Society Of Cardiology , European Society For Medical Oncology , Clinical Development Updates , Myokardia Inc , Exchange Commission , Astrazeneca , Research Development Expenses , European Society , Cardiology Congress , Chinese Demodex , Chief Executive Officer , Business Highlights , Mainland China , Medical Oncology , Greater China , Annual Report , Months Ended September , Clinical Development , Lianbio , Clinical Trial , Biotechnology Company ,